RICHARD M NOVICK
Veterinary in New York, NY

6337385, Jan 8, 2002

Jun 24, 1999

09/339511

Tom W. Muir - New York NY
Patricia Mayville - Mahwah NJ
Richard P. Novick - New York NY
Ronald Beavis - Winnipeg, CA
Guangyong Ji - Rockville MD

The Rockefeller University - New York NY
New York University - New York NY

A61K 3812

530317, 530331, 530323, 514 9, 514 11, 514 13, 514 18

The present invention provides a cyclic peptide comprising the structure: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH —X —Z—X —COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10. Methods of preparation including a cyclization protocol, and methods of use of the cyclic peptides of the invention are also disclosed.

6447786, Sep 10, 2002

May 22, 1997

08/861476

Richard P. Novick - New York NY
Guangyong Ji - Elmhurst NY
Ronald Beavis - Indianapolis IN

New York University - New York NY

A61K 39085

4242431, 530350, 530300, 530317, 530327, 530328, 530329, 4241841, 4241851, 4241901, 435 691, 435 693

This invention provides peptides which inhibit agr transcription in and thereby block the expression of virulence factors in , pharmaceutical compositions comprising these peptides, as well as methods for treating or preventing an infection or disease caused by using the peptides of the present invention.

2007018, Aug 9, 2007

Aug 25, 2005

11/212020

Tom Muir - New York NY, US
Patricia Mayville - Robbinsville NJ, US
Richard Novick - New York NY, US
Ronald Beavis - Winnipeg, CA
Guangyong Ji - North Potomac MD, US

A61K 38/12, A61K 31/43, A61K 31/545

514009000, 514192000, 514200000

The present invention provides a cyclic peptide comprising the structure: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH—X-Z-X—COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of to an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10. Methods of preparation including a cyclization protocol, and methods of use of the cyclic peptides of the invention are also disclosed.

6953833, Oct 11, 2005

Dec 27, 2001

10/032950

Tom W. Muir - New York NY, US
Patricia Mayville - Mahwah NJ, US
Richard P. Novick - New York NY, US
Ronald Beavis - Winnipeg, CA
Guangyong Ji - Rockville MD, US

The Rockefeller University - New York NY
New York University - New York NY

A61K038/12, A61K038/00, C07K016/00

530317, 530323, 530331, 514 9, 514 11, 514 15, 514 17

The present invention provides a cyclic peptide comprising the structure: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH—X-Z-X—COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10. Methods of preparation including a cyclization protocol, and methods of use of the cyclic peptides of the invention are also disclosed.

2002000, Jan 17, 2002

Jul 21, 1998

09/120030

BETH P GOLDSTEIN - TARRYTOWN NY, US
MICHAEL W CLIMO - RICHMOND VA, US
RICHARD P NOVICK - NEW YORK NY, US
GORDON L ARCHER - RICHMOND VA, US

A61K039/40, G01N033/569

424/165100, 435/007330

Lysostaphin is demonstrated to be a powerful anti-staphylococcal agent suitable for parenteral administration to mammals including humans. Low dosages, on the order of 0.5 - 45 mg/kg/day are sufficient to eradicate most staphylococcal infections. Lysostaphin is also effective against bacteria of this type which have developed resistance to conventional antibiotics such as penicillins and vancomycin. Lysostaphin analogues, such as variants and related enzymes, show similar activity.

2003007, Apr 24, 2003

Jul 23, 2002

10/201444

Richard Novick - New York NY, US
Guangyong Ji - Elmhurst NY, US
Ronald Beavis - Indianapolis IN, US

C07K001/00, C07K014/00, C07K017/00

530/350000

This invention provides peptides which inhibit agr transcription in and thereby block the expression of virulence factors in , pharmaceutical compositions comprising these peptides, as well as methods for treating or preventing an infection or disease caused by using the peptides of the present invention.

5633245, May 27, 1997

Jun 6, 1995

8/470997

Susan Brown-Skrobot - Hamilton NJ
Richard P. Novick - New York NY
Steven J. Projan - New York NY

Public Health Research Institute - New York NY

A61K 31545, A61K 3122, A61K 31225, A61K 3120

514199

A class of chemical compounds comprising fatty acid ester derivatives used to inhibit beta-lactamase production by infectious bacteria. These inhibitors have been found to retard the resistance of certain strains of bacteria to beta-lactam antibiotics, such as penicillin, by interfering with the transcription of the beta-lactamase gene and precluding expression of beta-lactamase. In accordance therewith, these inhibitors permit effective treatment of infections of otherwise resistive bacteria with antibiotics.